Take­da-part­nered Finch Ther­a­peu­tics grabs $36M and looks to leapfrog the pack in mi­cro­bio­me R&D

Close to a year af­ter Seres de­clared that it had jumped back on track af­ter a trou­bling set­back with its lead mi­cro­bio­me drug for Clostrid­i­um dif­fi­cile in­fec­tions, a dark horse in the pack is chal­leng­ing it for the lead in the emerg­ing field.

Four months af­ter merg­ing with Cresto­vo, Finch Ther­a­peu­tics has raised $36 mil­lion in Se­ries B mon­ey to hus­tle ahead with a mid-stage study of CP101 that got un­der­way last sum­mer. The “full spec­trum mi­cro­bio­ta” prod­uct was the main at­trac­tion for the merg­er, Finch CEO Mark Smith tells me, and re­placed their own ri­val ther­a­py in the pipeline.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN